Twenty-four new hybrid analogues (15–38) containing 7-chloro-4-aminoquinoline and
2-pyrazoline N-heterocyclic fragments were synthesized. Twelve of the new compounds were
evaluated against 58 human cancer cell lines by the U.S. National Cancer Institute (NCI).
Compounds 25, 30, 31, 36, and 37 showed significant cytostatic activity, with the most outstanding
GI50 values ranging from 0.05 to 0.95 µM. The hybrid compounds (15–38) were also evaluated for
antifungal activity against Candida albicans and Cryptococcus neoformans. From the obtained results
some structure–activity relationships were outlined.